Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | IDE | P14735 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 6/20 | 0.59 |
| ▸ | CA1 | P00915 | 6/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.59 |
| ▸ | CA9 | Q16790 | 6/20 | 0.59 |
| ▸ | HLCS | P50747 | 4/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.55 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12672576 | 0.90 | TDP1 (0.63) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1810465 | 0.89 | TDP1 (0.74) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL16063441 | 0.88 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13899175 | 0.88 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL19034459 | 0.88 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL23126169 | 0.88 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL23126156 | 0.88 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL8650557 | 0.88 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10051079 | 0.88 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL9412852 | 0.88 | TDP1 (0.74) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170071905-A1 | COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL | THE TEXAS A&M UNIVERSITY SYSTEM | 2017-03-16 | — | — | US | disclosed |
| US-7820797-B2 | the glycolipopeptide combines features from a B-epitope glycan or glycopeptide and a T-epitope peptide derived from glycoproteins of mammalian origin; for use as a therapeutic or prophylactic vaccine | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090041836-A1 | the glycolipopeptide combines features from a B-epitope glycan or glycopeptide and a T-epitope peptide derived from glycoproteins of mammalian origin; for use as a therapeutic or prophylactic vaccine | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041836-A1 | the glycolipopeptide combines features from a B-epitope glycan or glycopeptide and a T-epitope peptide derived from glycoproteins of mammalian origin; for use as a therapeutic or prophylactic vaccine | CD4, STT3A, UGCG | TDP1 3316/4885MEN1 2669/4885ABL1 4185/4885 |
| US-20170071905-A1 | COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL | ROS1, ABCC1, NQO1 | TDP1 3027/4885MEN1 4441/4885ABL1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.